{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:15:14Z","timestamp":1793502914730,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s10549-019-05458-8","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T13:50:16Z","timestamp":1572443416000},"page":"153-159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors"],"prefix":"10.1007","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6512-6008","authenticated-orcid":false,"given":"Elena","family":"Gonzalez-Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9reng\u00e8re","family":"Aubry-Rozier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Stoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2997-527X","authenticated-orcid":false,"given":"Khalil","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3684-2376","authenticated-orcid":false,"given":"Olivier","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,9]]},"reference":[{"issue":"7","key":"5458_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwinski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S (2017) 10\u00a0years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513\u2013523. \nhttps:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9992","key":"5458_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF, Austrian B, Colorectal Cancer Study G (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386(9992):433\u2013443. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(15)60995-3","journal-title":"Lancet"},{"issue":"8","key":"5458_CR3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C, Denosumab HPCSG (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361(8):745\u2013755. \nhttps:\/\/doi.org\/10.1056\/NEJMoa0809003","journal-title":"N Engl J Med"},{"key":"5458_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","volume":"7","author":"P Hadji","year":"2017","unstructured":"Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Gluer CC, de Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, Al-Daghri N, Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE (2017) Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 7:1\u201312. \nhttps:\/\/doi.org\/10.1016\/j.jbo.2017.03.001","journal-title":"J Bone Oncol"},{"issue":"11","key":"5458_CR5","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(18)30047-0","volume":"6","author":"TD Rachner","year":"2018","unstructured":"Rachner TD, Coleman R, Hadji P, Hofbauer LC (2018) Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol 6(11):901\u2013910. \nhttps:\/\/doi.org\/10.1016\/S2213-8587(18)30047-0","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"5458_CR6","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96(4):972\u2013980. \nhttps:\/\/doi.org\/10.1210\/jc.2010-1502","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"5458_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","volume":"43","author":"PD Miller","year":"2008","unstructured":"Miller PD, Bolognese MA, Lewiecki EM, McClung, Ding B, Austin M, Liu Y, San Martin J, Amg Bone Loss Study G (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43(2):222\u2013229. \nhttps:\/\/doi.org\/10.1016\/j.bone.2008.04.007","journal-title":"Bone"},{"issue":"1","key":"5458_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","volume":"17","author":"O Lamy","year":"2019","unstructured":"Lamy O, Stoll D, Aubry-Rozier B, Rodriguez EG (2019) Stopping denosumab. Curr Osteoporos Rep 17(1):8\u201315. \nhttps:\/\/doi.org\/10.1007\/s11914-019-00502-4","journal-title":"Curr Osteoporos Rep"},{"issue":"2","key":"5458_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, Roux C, Torring O, Valter I, Wang AT, Brown JP (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 33(2):190\u2013198. \nhttps:\/\/doi.org\/10.1002\/jbmr.3337","journal-title":"J Bone Miner Res"},{"issue":"2","key":"5458_CR10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/jc.2016-3170","volume":"102","author":"O Lamy","year":"2017","unstructured":"Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B (2017) Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab 102(2):354\u2013358. \nhttps:\/\/doi.org\/10.1210\/jc.2016-3170","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"5458_CR11","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 104(5):1595\u20131622. \nhttps:\/\/doi.org\/10.1210\/jc.2019-00221","journal-title":"J Clin Endocrinol Metab"},{"key":"5458_CR12","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2017.14484","author":"C Meier","year":"2017","unstructured":"Meier C, Uebelhart B, Aubry-Rozier B, Birkhauser M, Bischoff-Ferrari HA, Frey D, Kressig RW, Lamy O, Lippuner K, Stute P, Suhm N, Ferrari S (2017) Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO\/ASCO. Swiss Med Wkly. \nhttps:\/\/doi.org\/10.4414\/smw.2017.14484","journal-title":"Swiss Med Wkly"},{"key":"5458_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guanabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317. \nhttps:\/\/doi.org\/10.1016\/j.bone.2017.08.003","journal-title":"Bone"},{"issue":"5","key":"5458_CR14","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","volume":"27","author":"AW Popp","year":"2016","unstructured":"Popp AW, Zysset PK, Lippuner K (2016) Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int 27(5):1917\u20131921. \nhttps:\/\/doi.org\/10.1007\/s00198-015-3458-6","journal-title":"Osteoporos Int"},{"issue":"6","key":"5458_CR15","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","volume":"32","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 32(6):1291\u20131296. \nhttps:\/\/doi.org\/10.1002\/jbmr.3110","journal-title":"J Bone Miner Res"},{"key":"5458_CR16","doi-asserted-by":"publisher","first-page":"5432751","DOI":"10.1155\/2018\/5432751","volume":"2018","author":"E Gonzalez-Rodriguez","year":"2018","unstructured":"Gonzalez-Rodriguez E, Stoll D, Lamy O (2018) Raloxifene has no efficacy in reducing the high bone turnover and the risk of spontaneous vertebral fractures after denosumab discontinuation. Case Rep Rheumatol 2018:5432751. \nhttps:\/\/doi.org\/10.1155\/2018\/5432751","journal-title":"Case Rep Rheumatol"},{"key":"5458_CR17","volume-title":"Fracture risk after stopping adjuvant denosumab in hormone receptor positive breast cancer patients on aromatase inhibitor therapy\u2014an analysis of 3425 postmenopausal patients in the phase III ABCSG-18 trial","author":"G Pfeiler","year":"2018","unstructured":"Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, Wette V, Balic M, Haslbauer F, Bjelic-Radisic V, Bergh J, Jakesz R, Marth C, Sevelda P, Mlineritsch B, Exner R, Fesl C, Frantal S, Singer CF, Gnant M (2018) Fracture risk after stopping adjuvant denosumab in hormone receptor positive breast cancer patients on aromatase inhibitor therapy\u2014an analysis of 3425 postmenopausal patients in the phase III ABCSG-18 trial. American Society for Bone and Mineral Research, Montreal"},{"key":"5458_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.bone.2017.12.015","volume":"108","author":"A Leaney","year":"2018","unstructured":"Leaney A, Sztal-Mazer S (2018) Rebound vertebral fracture in the dental chair during a tooth extraction whilst on a treatment holiday from denosumab to avoid ONJ! Bone 108:43. \nhttps:\/\/doi.org\/10.1016\/j.bone.2017.12.015","journal-title":"Bone"},{"issue":"3","key":"5458_CR19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00198-017-4334-3","volume":"29","author":"R Niimi","year":"2018","unstructured":"Niimi R, Kono T, Nishihara A, Hasegawa M, Kono T, Sudo A (2018) Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis. Osteoporos Int 29(3):769\u2013772. \nhttps:\/\/doi.org\/10.1007\/s00198-017-4334-3","journal-title":"Osteoporos Int"},{"issue":"1","key":"5458_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00223-018-0389-1","volume":"103","author":"L Tripto-Shkolnik","year":"2018","unstructured":"Tripto-Shkolnik L, Rouach V, Marcus Y, Rotman-Pikielny P, Benbassat C, Vered I (2018) Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates. Calcif Tissue Int 103(1):44\u201349. \nhttps:\/\/doi.org\/10.1007\/s00223-018-0389-1","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"5458_CR21","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1210\/jc.2010-1805","volume":"96","author":"PD Miller","year":"2011","unstructured":"Miller PD, Wagman RB, Peacock M, Lewiecki EM, Bolognese MA, Weinstein RL, Ding B, San Martin J, McClung MR (2011) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 96(2):394\u2013402. \nhttps:\/\/doi.org\/10.1210\/jc.2010-1805","journal-title":"J Clin Endocrinol Metab"},{"key":"5458_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bone.2019.03.019","volume":"123","author":"A Fassio","year":"2019","unstructured":"Fassio A, Adami G, Benini C, Vantaggiato E, Saag KG, Giollo A, Lippolis I, Viapiana O, Idolazzi L, Orsolini G, Rossini M, Gatti D (2019) Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women. Bone 123:191\u2013195. \nhttps:\/\/doi.org\/10.1016\/j.bone.2019.03.019","journal-title":"Bone"},{"key":"5458_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-04820-8","author":"O Lamy","year":"2019","unstructured":"Lamy O, Fernandez-Fernandez E, Monjo-Henry I, Stoll D, Aubry-Rozier B, Benavent-Nunez D, Aguado P, Gonzalez-Rodriguez E (2019) Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports. Osteoporos Int. \nhttps:\/\/doi.org\/10.1007\/s00198-018-04820-8","journal-title":"Osteoporos Int"},{"issue":"9","key":"5458_CR24","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","volume":"28","author":"B Uebelhart","year":"2017","unstructured":"Uebelhart B, Rizzoli R, Ferrari SL (2017) Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates. Osteoporos Int 28(9):2701\u20132705. \nhttps:\/\/doi.org\/10.1007\/s00198-017-4080-6","journal-title":"Osteoporos Int"},{"issue":"1","key":"5458_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00223-018-0404-6","volume":"103","author":"AM Horne","year":"2018","unstructured":"Horne AM, Mihov B, Reid IR (2018) Bone loss after romosozumab\/denosumab: effects of bisphosphonates. Calcif Tissue Int 103(1):55\u201361. \nhttps:\/\/doi.org\/10.1007\/s00223-018-0404-6","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"5458_CR26","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1007\/s00198-017-4108-y","volume":"28","author":"T Lehmann","year":"2017","unstructured":"Lehmann T, Aeberli D (2017) Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures. Osteoporos Int 28(10):3067\u20133068. \nhttps:\/\/doi.org\/10.1007\/s00198-017-4108-y","journal-title":"Osteoporos Int"},{"issue":"4","key":"5458_CR27","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","volume":"101","author":"IR Reid","year":"2017","unstructured":"Reid IR, Horne AM, Mihov B, Gamble GD (2017) Bone loss after denosumab: only partial protection with zoledronate. Calcif Tissue Int 101(4):371\u2013374. \nhttps:\/\/doi.org\/10.1007\/s00223-017-0288-x","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"5458_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00223-018-0436-y","volume":"103","author":"E Tsourdi","year":"2018","unstructured":"Tsourdi E, Zillikens MC (2018) Certainties and uncertainties about denosumab discontinuation. Calcif Tissue Int 103(1):1\u20134. \nhttps:\/\/doi.org\/10.1007\/s00223-018-0436-y","journal-title":"Calcif Tissue Int"},{"key":"5458_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000979","author":"P Anagnostis","year":"2019","unstructured":"Anagnostis P, Paschou SA, Gonzalez-Rodriguez E, Potoupnis M, Tsiridis E, Lamy O, Goulis DG (2019) Spontaneous vertebral fractures in males with osteoporosis after denosumab discontinuation: a report of two cases. J Clin Rheumatol. \nhttps:\/\/doi.org\/10.1097\/RHU.0000000000000979","journal-title":"J Clin Rheumatol"},{"key":"5458_CR30","volume-title":"Can we avoid the loss of bone mineral density one year after denosumab discontinuation? the reolaus bone project","author":"G Liebich","year":"2019","unstructured":"Liebich G, Stoll D, Stoll D, Gonzalez-Rodriguez E, Gonzalez-Rodriguez E, Hans D, Lamy O, Aubry-Rozier B, Aubry-Rozier B (2019) Can we avoid the loss of bone mineral density one year after denosumab discontinuation? the reolaus bone project. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Paris"},{"issue":"8","key":"5458_CR31","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ, Group AMGBLS (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354(8):821\u2013831. \nhttps:\/\/doi.org\/10.1056\/NEJMoa044459","journal-title":"N Engl J Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05458-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-019-05458-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05458-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T19:22:03Z","timestamp":1602098523000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-019-05458-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,9]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["5458"],"URL":"https:\/\/doi.org\/10.1007\/s10549-019-05458-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,9]]},"assertion":[{"value":"18 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"EGR, BAR, DS, KZ, and OL declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Studies were in accordance with the ethical standards of the institutional research committee (CER-VD 2017-02135) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}